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industrial partner. Some of the work was 




The	 phospholipid	 l-	α-	lysophosphatidylinositol	 (LPI),	 an	 endogenous	 ligand	 for	
GPR55,	 is	 elevated	 in	 patients	 with	 acute	 coronary	 syndrome,	 and	 a	 GPR55	 an-
tagonist	 cannabidiol	 (CBD)	 reduces	experimental	 ischemia/reperfusion	 (I/R)	 injury.	
While	LPI	activates	multiple	signaling	pathways,	little	is	known	about	which	ones	are	
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1  | INTRODUC TION
Reperfusion of an occluded artery is vital to the salvage of the 
myocardium	 affected	 by	 ischemia,	 however	 the	 reintroduction	
of	blood	and	oxygen	paradoxically	causes	further	 injury	and	car-
diomyocyte	 death	 known	 as	 ischemia/reperfusion	 (I/R)	 injury.12 
Immediate “lethal” I/R injury occurs within the first few minutes 
of reperfusion with the critical early events being an increase in 
oxidative	stress,	 [Ca2+]i	overload,
13 opening of the mitochondrial 
permeability	 transition	pore	 (MPTP15)	and	 the	activation	of	pro-	
apoptotic pathways.14,26 It is well established that the release of 
bioactive lipids from platelets at the site of clot formation during 
acute	 myocardial	 infarction	 (AMI)	 contributes	 to	 the	 eventual	
extent	of	myocardial	I/R	injury,	with	some	lipids	(eg	sphingosine-	
1-	phosphate;	 S-	1-	P)	 exerting	 cardioprotective	 effects	 (reviewed	
in	 21)	 and	 others	 exacerbating	 (eg	 platelet	 activating	 factor:	
22,32)	 I/R	 injury.	Platelets	also	 release	 the	 lysophospholipid	 l-	α-	
lysophosphatidylinositol	 (LPI)	 and	 are	 thought	 to	 be	 the	 source	
of	 the	elevated	plasma	 levels	of	LPI	 seen	 in	patients	undergoing	
coronary	 angioplasty	 for	 acute	 coronary	 syndrome	 (ACS27).	 LPI	
acts	 as	 an	endogenous	 ligand	at	 the	G-	protein	 coupled	 receptor	
GPR5536	which	is	expressed	in	various	rodent40 and human18 tis-
sues	including	the	cardiovascular	system,	where	it	is	expressed	on	
vascular smooth muscle and endothelial cells6,7 and ventricular 
cardiomyocytes.45,52
Although	the	functional	importance	of	the	GPR55/LPI	system	
in cardiovascular physiology and pathophysiology is poorly under-
stood,	we	have	previously	shown	that	mice	lacking	GPR55	exhibit	
moderate systolic dysfunction with age and have a decreased 
contractile	 reserve	 in	 response	 to	 adrenoceptor	 stimulation,45 
suggesting a physiological role in maintaining cardiac function. In 
contrast,	observations	that	GPR55	tissue	expression	and	circulat-
ing	levels	of	LPI	are	raised	in	conditions	where	there	is	heightened	
cardiovascular	 risk	 (such	 as	 obesity	 and	metabolic	 syndrome33);	
that	 cardiac	 LPI	 levels	 rise	 during	 asphyxia-	induced	 myocardial	
ischemia,24,25	and	that	 the	GPR55	antagonist	CBD	reduces	myo-
cardial infarct size in rats in vivo9,46 all point to a potential detri-
mental	 role	 for	LPI/GPR55	 in	cardiovascular	pathologies	 such	as	
AMI.
Studies	 in	 GPR55-	expressing	 HEK	 cells	 have	 linked	 GPR55-	
mediated	 LPI	 responses	 to	 activation	 of	 several	 signaling	 path-
ways,	 including	 activation	 of	 RhoA	 and	 ROCK	 resulting	 in	 an	
increase	 in	 intracellular	calcium	 ([Ca2+]i)	 and	activation	of	Gα13.
17 
Similarly,	 LPI	 induces	 a	 rapid	 and	 transient	 increase	 in	 [Ca2+]i in 
cardiomyocytes	 through	 an	 action	 at	 GPR55	 receptors	 located	
on both the sarcolemma and the membranes of intracellular or-
ganelles,52	although	any	involvement	of	RhoA/ROCK	signaling	in	
the	response	to	LPI	in	cardiomyocytes	remains	to	be	investigated.	
[Ca2+]i overload is a major factor in cardiomyocyte death follow-
ing myocardial I/R5,28	and	activation	of	the	RhoA/ROCK	pathway	










detection of integrated cellular responses in living cells.41 This al-
lowed us to make a rapid determination of the optimum concen-
tration	and	exposure	time	to	LPI	for	subsequent	studies	in	murine	
iPSC	 cardiomyocytes	 and	 isolated	 Langendorff-	perfused	 hearts,	
which	were	undertaken	to	confirm	that	stimulation	of	GPR55	by	
LPI	 leads	 to	 activation	 of	 the	 RhoA/ROCK/p38	MAPK	 pathway	
and	to	an	exacerbation	of	myocardial	injury	in	cultured	cardiomy-
ocytes	and	isolated	hearts,	respectively.
2  | MATERIAL S AND METHODS
2.1 | Dynamic mass redistribution (DMR) in 
response to LPI
The	underlying	principle	of	determining	changes	in	cellular	DMR	has	
previously been described in detail.10,11,41	To	measure	DMR,	cells	are	
seeded on to a microplate containing a resonant waveguide grating 
biosensor,	which	measures	changes	in	the	local	 index	of	refraction	
upon mass redistribution within a living cell monolayer grown on the 
biosensor.	When	a	receptor	is	stimulated	by	a	ligand,	the	change	in	
DMR	in	the	cells	is	manifested	as	a	shift	in	the	wavelength	of	light	
that is reflected from the sensor. The magnitude of this wavelength 
shift	is	proportional	to	the	total	change	in	the	biomass	proximal	to	
the	 sensor	 surface	 (amount	 of	DMR)	 and	 thus	GPCR	 activation	 is	
translated	 into	 signaling	 pathway-	specific	 optical	 signatures.	 This	
technique	 has	 been	 previously	 used	 to	 demonstrate	 activation	 of	
GPR55	 in	 other	 cell	 types,19	 but	 not	 in	 cardiomyocytes,	 and	 has	
been	 identified	 as	 the	 preferred	 assay	 technique	 to	 study	GPR55	
pharmacology and function since it provides a much more accu-
rate	 determination	 of	 agonist	 potency.	 In	 the	 present	 studies,	 to	
measure	the	DMR	in	response	to	LPI,	murine	(Cor.At®	CL-	i;	source	
tissue	mouse	 tail	 tip;	miPSC)	 and	 human(iCell®;	 1099441;	 hiPSC)-	
induced	 pluripotent	 stem	 cell	 (iPSC)	 cardiomyocytes	were	 seeded	
(miPSCs—7500	per	well;	hiPSCs—12,000	per	well)	in	Epic® 384 Well 
fibronectin	coated	cell	assay	microplates	using	a	Multi-	drop	Combi	





















cardiomyocytes	 exposed	 to	 CBD	 (1	 μmol	 L−1)	 or	 Y-	27632	 (10	 and	
50	μmol	L−1)	for	90	minutes	was	determined	using	an	MTT	(3-	(4,5-	d
imethylthiazol-	2-	yl)-	2,5-	diphenyltetrazolium	bromide)	assay.	Briefly,	
miPSC	 cardiomyocytes	were	 seeded	 at	 a	 density	 of	 20,000	 cells/
well	 in	a	96-	well	plate	and	cultured	 in	Cor.At®	media	 (supplied	by	
the	manufacturer)	for	7	days	at	37°C	(in	5%	CO2).	Following	treat-




2.2 | Activation of downstream signaling pathways 
by LPI in miPSC cardiomyocytes
Activation	of	ROCK,	p38	MAPK,	 JNK,	 and	caspase-	3	 cleavage	 in	
response	to	LPI	stimulation	was	determined	in	miPSC	cardiomyo-
cytes	cultured	as	described	in	Section	2.1.	Experiments	were	per-
formed	 with	 cells	 grown	 at	 a	 confluency	 of	 70%-	80%	 and	 then	
serum	 starved	 overnight	 (16	 hours)	 prior	 to	 experimentation.	
Following	challenge	with	LPI,	with	or	without	the	ROCK	inhibitor	





1	mmol	 L−1	 sodium	orthovanadate,	1	mmol	 L−1	EDTA,	1	mmol	 L−1 
EGTA,	 10	mmol	 L−1	 sodium	2-	glycerophosphate,	 50	mmol	 L−1 so-
dium	 fluoride,	5	mmol	L−1	 sodium	pyrophosphate,	1%	 (v/v)	Triton	
X-	100,	 0.1%	 (v/v)	 2-	mercaptoethanol	 and	 protease	 inhibitor	 (one	
tablet/50	 mL)).	 Cell	 debris	 was	 removed	 from	 crude	 cell	 lysates	
by centrifugation at 3000g	 for	10	minutes	at	4°C,	and	the	result-
ing	 supernatant	 used	 for	 Western	 blot	 analysis.	 Proteins	 from	
cell	 lysates	 (30	μg)	were	 fractionated	 by	 SDS-	polyacrylamide	 gel	
electrophoresis	and	immunoblotted	using	anti-	phospho	(Ser1366)	
ROCK2	 (Genetex,	 Irvin,	 CA,	USA),	 anti-	Actin	 (MilliporeSigma,	 St.	




Danvers,	 MA,	 USA)	 antibodies.	 Primary	 antibody	 detection	 was	
carried	out	using	a	horseradish	peroxidase-	conjugated	anti-	rabbit	
IgG	antibody	(New	England	Biolabs,	Hitchin,	Herts,	UK)	and	visu-




All	 studies	 were	 performed	 under	 a	 Project	 License	 authorized	
under	 the	 UK	 Animals	 (Scientific	 Procedures)	 Act	 1986,	 conform	
to	 the	 guidelines	 from	 Directive	 2010/63/EU	 of	 the	 European	
Parliament	on	the	protection	of	animals	used	for	scientific	purposes	
and	are	reported	in	line	with	the	ARRIVE	guidelines.23	Male	and	fe-
male	wild	 type	 (WT)	mice	 (C57BL/6J;	 JAX	background)	were	pur-
chased	from	Charles	River	Laboratories	International	Inc.	(Margate,	
UK),	 while	 homozygous	 GPR55	 knockout	 (GPR55−/−;	 JAX	 back-
ground)	mice	were	bred	in-	house	and	were	routinely	genotyped	as	
previously described.49	 All	 animals	were	 housed	 in	 the	University	
of	 Aberdeen	 Medical	 Research	 Facility	 until	 experimentation	 at	
Robert	 Gordon	 University.	 All	 mice	 were	 grouped	 according	 to	
genotype,	 gender	 and	 age	 and	 housed	 in	 temperature	 (21	 ±	 2°C)	
and	 humidity	 (55	 ±	 10%)	 controlled	 rooms	 with	 a	 12-	hour	 light/
dark	cycle	 (7	am/7	pm).	Additionally,	mice	were	housed	(according	
to	husbandry	guidelines	set	by	the	UK	Home	Office)	in	groups	not	












25	mmol	 L−1	NaHCO3,	 2.52	mmol	 L
−1 CaCl2	 and	 10.88	mmol	 L
−1 
C6H12O6;	 pH	 7.4;	 37°C;	 2-	2.5	 mL/min).	 Following	 a	 15-	minute	
stabilization	 period,	 since	 flow	 to	 the	 heart	 was	 to	 be	 stopped	
during	global	 ischemia,	a	slow	bolus	 injection	of	LPI	 (500	μL	of	a	
10 μmol	L−1	solution	over	a	30	second	period)	or	vehicle	 (500	μL	
of	0.1%	DMSO)	was	administered	via	a	side-	port	of	the	aortic	can-
nula	 10	minutes	 prior	 to	 30	minutes	 of	 no-	flow	 global	 ischemia	
followed	by	30	minutes	reperfusion.	This	concentration	of	LPI	was	






thickness)	 and	 the	 third	 section	 from	 the	 apex	 stained	 with	
2,3,5-	Triphenyl-	tetrazolium	chloride	 (TTC;	1%)	 for	30	minutes	at	





termined	 via	 computerized	 planimetry	 (ImageJ	 software)	 where	
red and white staining was indicative of healthy and infarcted tis-
sue,	respectively.





were	expressed	as	 a	 ratio	of	phospho-	ROCK2	 to	ROCK2.	For	 the	




mum before either reaching a plateau or declining; n refers to the 
number	 of	 plates	 tested	 for	 each	 intervention.	 For	 isolated	 heart	




employed hearts from at least five animals for each intervention. 
However,	 since	 the	 studies	were	 performed	 over	 several	months,	
contemporaneous	 control	 experiments	 in	wild	 type	mice	were	 in-
cluded throughout to avoid any influence of seasonal variation 
and	therefore	the	data	were	pooled,	resulting	in	larger	group	sizes.	
Infarct	 size	 is	 expressed	 as	 a	 percentage	 of	 total	 ventricular	 area	
of	the	tissue	slice.	For	both	cell	studies	and	isolated	heart	studies,	
comparisons	were	made	using	either	Student's	unpaired	t-	test	(two-	
group	 comparison)	 or	 one-	way	 ANOVA	 followed	 by	 a	 Bonferroni	









NaHCO3)	 were	 all	 purchased	 from	 Sigma	 Aldrich
®,	 UK.	 Ketamine	
(Vetalar™)	 and	 Xylazine	 (Rompun®)	 were	 obtained	 from	 Pfizer	 and	




was	 bought	 from	 Invitrogen,	 UK.	 Corning®	 Epic®	 384	 Well	 Cell-	
Based	Assay	Microplates	were	acquired	from	Corning	Life	Sciences,	
UK.	 Human	 iPSC	 Cardiomyocytes	 (hiPSC	 cardiomyocytes;	 iCell® 
Cardiomyocytes)	were	acquired	from	Cellular	Dynamics®,	US.
3  | RESULTS
3.1 | Effect of LPI on cultured cardiomyocytes—




Concentration-	response	 studies	 in	 murine	 iPSC	 cardiomyocytes	
demonstrated	 that	 LPI-	induced	 DMR	 activity	 in	 a	 concentration-	
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in	onset,	 reached	peak	activity	at	10	minutes	post	application	and	
persisted	 for	 the	duration	of	 the	period	of	measurement	 (90	min-
utes;	Figure	1B).	Since	data	from	clinical	cases	of	acute	coronary	syn-
drome	have	found	plasma	LPI	levels	to	be	in	the	region	of	1-	12	μmol 
L−1,27 we chose to use 10 μmol	L−1	LPI	for	subsequent	experiments	
since this is in the upper range of clinical data and produced a re-
sponse	of	 sufficient	magnitude	 and	duration	 (Figure	1C	 and	D)	 to	
be sustained throughout the I/R protocol used in the isolated heart 
studies	(70	minutes	in	total).
Both	the	peak	(Figure	2A)	and	time-	dependent	(Figure	2B)	DMR	






L−1	 shown	 in	 (Figure	 2C	 and	 D),	 demonstrating	 that	 LPI	 activates	
ROCK	 downstream	 of	 GPR55	 in	 murine	 iPSC	 cardiomyocytes.	
Neither	CBD	(10	μmol	L−1)	nor	Y-	27632	(10	μmol	L−1	and	50	μmol	L−1)	









3.2 | LPI induces ROCK and p38 MAPK 
phosphorylation in murine iPSC cardiomyocytes
To	confirm	that	the	changes	in	DMR	in	response	to	LPI	were	indeed	









significant	 alterations	 in	 either	 JNK	 phosphorylation	 or	 caspase-	3	
activation	(Figure	4	D	and	E).
To	demonstrate	that	ROCK	activation	persists	for	the	duration	
of global ischemia during the I/R protocol to be used in the subse-
quent	 isolated	 perfused	 heart	 experiments,	 ROCK	 activation	 was	






role	of	GPR55	 in	mediating	 the	 responses	 to	LPI	was	 further	con-
firmed	in	these	experiments	by	using	the	selective	GPR55	antago-
nist	CID16020046	(10	μmol	L−1).	ROCK	phosphorylation	by	LPI	was	




3.3 | LPI exacerbates I/R injury via activation of 
GPR55 and ROCK phosphorylation
To	 confirm	 that	 LPI	was	 acting	 through	GPR55,	 hearts	 from	both	
WT	and	GPR55−/−	mice	were	used.	Challenging	WT	hearts	with	LPI	




the	 hearts	 within	 the	 first	 1-	2	 minutes	 of	 reperfusion,	 there	 was	





or	 vehicle,	 the	 LPI-	induced	 exacerbation	 of	 infarct	 size	was	 abro-
gated	by	the	higher	concentration	(Figure	6C,	D	and	H),	implicating	
ROCK	in	the	signaling	pathway	downstream	of	GPR55.	Interestingly,	
infarct	 size	 did	 not	 significantly	 differ	 between	 vehicle-	treated	
hearts	from	WT	and	GPR55−/−	mice.	This	 indicates	that,	at	 least	 in	
isolated	hearts,	 the	 induction	of	 ischemia	does	not	 induce	cardiac	
release	of	LPI.
4  | DISCUSSION AND CONCLUSIONS
The data presented from this study has shown for the first time that 
LPI,	 a	 platelet-	derived	 lysophospholipid	 that	 is	 elevated	 in	 acute	
coronary	syndrome,	exacerbates	the	extent	of	myocardial	injury	and	
that,	as	 in	other	cell	 types,	LPI	exerts	 its	cellular	 responses	 in	car-
diomyocytes	via	activation	of	the	GPR55	receptor	and	downstream	
activation	of	both	ROCK	and	p38	MAPK.
4.1 | LPI signaling in cardiomyocytes
Despite	 strong	 evidence	 that	 LPI-	induced	 RhoA/ROCK	 signaling	
is	 important	 in	 other	 cell	 types,	 this	 pathway	 has	 not	 previously	
been	 investigated	 in	 cardiomyocytes.	 Using	 a	 high-	throughput	
(Corning®Epic®)	technique41	to	measure	DMR,	which	has	previously	
been	 used	 to	 explore	 cellular	 responses	 to	GPR55	 ligands	 (includ-
ing	 LPI),19	 we	 have	 demonstrated	 the	 concentration	 dependency,	
time	course,	and	the	magnitude	of	the	LPI	response	 in	murine	and	




sistent with studies in both cancer3	and	HEK29317,19	cells.	Crucially,	
we	were	able	to	establish	identical	responses	to	LPI,	and	blockade	by	








groups. #P < 0.001 vs vehicle; *P <	0.001	vs	LPI	alone.	AU=Arbitrary	Units



























































Y-27632 (10 µmol/L) +
LPI (10 µmol/L)


























LPI (10 µmol/L) +
Y-27632 (10 µmol/L)




































































the	induction	of	apoptosis,39 however we did not see any activation 
of	JNK	or	caspase-	3	(both	markers	of	apoptosis),	suggesting	that	the	
increased	injury	seen	in	the	isolated	hearts	challenged	with	LPI	prior	
to I/R was not due to induction of apoptotic cell death but to some 
other	mechanism,	such	as	calcium	overload.	It	has	been	previously	






channels.52 There is generally scant information on any association 
between	ROCK	activation	and	increases	in	[Ca2+]i,	and	indeed	RhoA	
and Ca2+ signaling pathways have been traditionally regarded as 
being	distinct	from	each	other,	and	so	quite	how	LPI-	induced	ROCK	
activation	links	to	the	reported	LPI-	induced	increases	in	cardiomyo-
cyte [Ca2+]i	 remains	 elusive.	However,	 a	 link	 between	ROCK	 acti-
vation and increases in [Ca2+]i	has	been	seen	in	HEK	cells,	where	a	
RhoA-	dependent	 Ca2+	 signaling	 pathway	 mediates	 LPI-	induced	
NFAT	activation,17 suggesting that in some tissues these pathways 
converge.	 Indeed,	 LPI	 causes	 a	 biphasic	 increase	 in	 [Ca2+]i,	 in	 en-
dothelial	 cells,	 the	 first	 phase	 of	which	 is	 PLC-	IP3-	dependent	 and	







we have found previously in rat neonatal cardiomyocytes that the 
activation	of	ERK	in	response	to	LPI	is	very	transient	(5	minutes)	and	
would therefore be unlikely to account for the sustained response to 
LPI	seen	in	the	DMR	studies	(Figure	S1;	unpublished	observations).
4.2 | Mechanisms of LPI- induced 
cardiomyocyte injury
Total	 levels	 of	 LPI	 in	 the	 coronary	 circulation	 during	AMI	 are	 sig-
nificantly	elevated	(mean	2.95	±	1.88	μmol	L−1;	range	1-	12	μmol	L−1),	
compared to levels seen in either stable angina or no coronary ar-
tery	disease	(mean	1.54	±	0.99	μmol	L−1;	range	1-	5	μmol	L−1	27)	and	
it	is	believed	that	the	LPI	is	released	from	platelets	activated	at	the	
site	of	plaque	rupture	and	clot	 formation,	 rather	 than	the	myocar-
dium per se.	Platelet-	derived	substances	released	during	AMI	have	
ready	 access	 (via	 the	 coronary	 circulation)	 to	 the	 cardiac	 tissue	 in	
the vicinity of their release and therefore could influence the in-






in	all	experiments.	Values	are	shown	as	mean	±	SEM;	n	=	4	experiments	performed	using	separate	cell	preparations	for	all	groups.	*P < 0.001 
vs vehicle; #P <	0.001	vs	LPI	alone.	AU	=	Arbitrary	Units
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coronary	circulation	(to	mimic	exposure	to	platelet-	derived	LPI),	has	














fact significantly lower than in sham hearts. Our studies also show 
that	 administration	of	 LPI	 at	 the	 time	of	 reperfusion	does	not	ex-
acerbate	 the	 extent	 of	 injury,	 demonstrating	 that	 the	 LPI-	induced	
increase in myocardial injury occurs during ischemia.
We have also confirmed that the increase in infarct size fol-
lowing	LPI	application	to	isolated	hearts	is	via	activation	of	GPR55	





tissue or in vivo	studies	it	displays	a	more	complex	pharmacology.47 
Moreover,	 CBD	 itself	 reduces	 infarct	 size9,46 through mechanisms 
that	are	not	exclusively	GPR55-	mediated,	and	which	could	have	con-
founded the present studies.
The	amelioration	of	the	infarct-	extending	effect	of	LPI	in	WT	
hearts	 by	 the	ROCK	 inhibitor	Y-	27632	 supports	 the	notion	 that	
cardiomyocyte	ROCK	activation	by	LPI	is,	at	least	in	part,	respon-
sible	 for	 the	 exacerbation	 of	 I/R	 injury.	 ROCK	 expression	 is	 in-
creased in the postinfarct heart29 and there is strong evidence that 
ROCK	activation	is	an	important	contributor	to	the	expansion	of	
I/R	injury,	since	ROCK	inhibition	reduces	I/R	injury	through	multi-
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have	 shown	 that	 LPI	 similarly	 induces	 p38	 MAPK	 activation	 in	
cultured	miPSC	cardiomyocytes	downstream	of	ROCK	activation,	
although this is not associated with induction of apoptotic signal-
ing	 pathways	 (JNK	 and	 caspase-	3).	However,	 p38	MAPK	 inhibi-
tion during I/R has been shown to prevent mitochondrial reactive 
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possible	mechanism	underlying	 the	 LPI-	induced	exacerbation	of	
injury.
LPI	 also	promotes	Ca2+	 entry	 (via	LTCCs52)	 into	cardiomyocytes,	
which in the setting of I/R would induce cellular injury through the in-





to	ROCK	activation	 in	 vascular	 smooth	muscle	 cells.31	Moreover,	 in	
GPR55-	expressing	HEK	cells	LPI	activates	phospholipase	C	(PLC)	via	
a	ROCK-	dependent	pathway,19	with	the	subsequent	production	of	IP3 
and stimulated Ca2+	 release	 from	 the	 sarcoplasmic	 reticulum,	which	
again would cause Ca2+	overload.	ROCK	has	also	been	shown	to	work	
in	 concert	with	 low	 voltage-	activated	 T-	type	Ca2+	 channels	 (Cav3.2	






effect	 of	ROCK	 inhibition,	we	did	 not	 see	 an	 infarct-	reducing	 ef-
fect	 of	 Y-	27632	 but	 rather	we	 observed	 a	 slight	 (not	 statistically	
significant)	trend	toward	an	increase	in	infarct	size.	There	are	sev-
eral	plausible	explanations	for	this.	First,	ROCK	inhibition	has	been	
shown to decrease infarct size and preserve postinfarction cardiac 
systolic function through various mechanisms including increased 
collateral	blood	flow	to	the	myocardium,51 improved metabolic sta-
tus	of	the	ischemic	tissue,16	reduced	myocardial	fibrosis,29 reduced 
apoptosis and inflammation4 and preservation of the reperfusion 
injury	 salvage	 kinase	 (RISK)	 pathway.30	 Importantly,	 all	 of	 these	
studies used in vivo	models	and	determined	end	points	(inflamma-
tion	and	apoptosis)	that	occur	over	extended	periods	of	time	(hours	
to	days)	after	 reperfusion	or	 implemented	ROCK	 inhibition	at	 the	
time of reperfusion.14	 In	 contrast,	 our	 studies	were	performed	 in	





cyte	 survival	 via	 a	 PKD	pathway50 and more recent studies have 
shown	that	the	two	ROCK	isoforms	(ROCK-	1	and	ROCK-	2)	play	op-
posing	roles	 in	 the	heart,	with	ROCK-	1	protecting	against	cardiac	
dysfunction	 and	oxidative	 stress	 and	ROCK-	2	 promoting	 these.43 
Since	Y-	27632	is	a	nonselective	inhibitor	that	has	similar	affinities	
for	both	ROCK	isoforms,2	this	could	explain	why	in	vehicle-	treated	
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did	not	employ	a	preconditioning	protocol,	inhibition	of	PKN	would	
be	 the	most	 likely	 alternative	mechanism	 of	 the	 infarct-	extending	
effect	of	Y-	27632.
In	 summary,	 we	 present	 the	 novel	 finding	 that	 LPI	 activates	
murine	and	human-	induced	pluripotent	stem	cell	cardiomyocytes	
via	 a	 GPR55/RhoA/ROCK/p38	 MAPK-	dependent	 pathway,	 and	
that	this	same	pathway	is	responsible	for	the	exacerbation	of	 in-
jury	seen	in	hearts	challenged	with	LPI	prior	to	an	ischemia/reper-
fusion insult. While the precise signaling pathways that ultimately 
result	in	a	greater	injury	response	following	LPI	challenge	remain	
to	be	elucidated,	based	upon	the	knowledge	of	signaling	pathways	
in	 other	 cell	 types	 we	 hypothesize	 (Figure	 7)	 that	 LPI	 activates	
ROCK	both	directly	and	indirectly	(via	Ca2+	entry),	which	(i)	further	
increases [Ca2+]i	 through	 IP3-	mediated	 release	 from	 intracellular	




at	 clinically	 relevant	 concentrations,	 induces	 activation	 in	 human-	
induced pluripotent stemcell cardiomyocytes through precisely the 
same mechanism as that seen in murine cells. When taken alongside 
reports	that	LPI	levels	are	increased	in	the	coronary	circulation	in	pa-
tients	with	ACS,	our	data	implicate	LPI	as	a	contributor	to	the	extent	
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